The latest announcement is out from SAB Biotherapeutics (SABS).
SAB Biotherapeutics has successfully completed the third cohort dosing in phase one trials for their new drug, SAB-142, without any cases of serum sickness reported. The company plans to release a detailed corporate update mid-April, which could be a significant point of interest for investors and followers of the biotech industry.
For an in-depth examination of SABS stock, go to TipRanks’ Stock Analysis page.